Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Trial Profile

An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per the results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=74) assessing safety and efficacy at the end of 2 year presented at the 42nd European Society for Medical Oncology Congress
    • 08 Feb 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top